GMA-8015

Murine Anti- Factor VIII

Clone GMA-8015

Background

Factor VIII (FVIII) is a heterodimer consisting of a heavy chain (ranging in mass from 90 to 200 kDa) bound via metal ions to a light chain (80 kDa). In plasma, FVIII circulates in an inactive form bound to von Willebrand factor. Following activation by factor Xa or thrombin, factor VIIIa can function as cofactor for the enzyme factor IXa in the activation of factor X in the presence of phospholipid and Ca2+ . Absent or defective FVIII is the cause of the X-linked recessive bleeding disorder hemophilia A. GMA- 8015 (also known as 4A4 or 4A4.2B) recognizes the A2 domain of FVIII, inhibits FVIII activation of factor X, and binds human, murine, and rhesus FVIII by ELISA

More Information:

Product Datasheet, pdf

Description

Species Reactivity: Human, Mouse
Source: Murine
Specificity: A2 domain
Immunogen: B-domain deleted recombinant Human Factor VIII
Isotype: IgG2a

Application

ELISA: Binds the A2 domain of recombinant human factor VIII in solid-phase ELISA.
Immunoblotting: Not recommended.
Inhibition: Strongly inhibitory in aPTT clotting assay.1

Data:

Purchase GMA-8015

  • 0.1 mg/$265.00
  • 0.5 mg/$660.00
For Larger Amounts Please Call:
(802) 865-6230
Quantity:
Continue Shopping

Antibody References:

  1. R.C. Markovitz et al. (2013). Blood. 121(14):2785-2795.
  2. R.J. Summers et al. (2011). Blood. 117(11):3190-3198.
  3. L. Ivanciu et al. (2011). NatBiotechnol. 29(11):1028-1033.
  4. T. Wyseure et al. (2019). JCI Insight. 4(19):1-18.
  5. J. Rayes et al. (2018). Haematologica. 103(2):351-360.
  6. S. Keshava et al. (2017). Blood Advances. 1(15):1206-1214.
  7. R.M. Schoeman et al (2017). Cellular and Molecular Bioengineering. 10(1):3–15.
  8. B. Gangadharan et al. (2017). Haematologica. 102(2):271-281.
  9. Q. Wang et al. (2016). Gene Ther. 23(7):597–605.
  10. S. Krishnamoorthy et al. (2016). Cell Immunol. 301:30–39.
  11. S. Keshava et al. (2016). J Thromb Haemost. 14(3):546-550.
  12. V. Bhat et al. (2016). Thromb Haemost. 115(3):551–561.
  13. J. Firrman et al. (2020). Molecular Therapy: Methods & Clinical Development. 17:328-336.
  14. S. Delignat et al. (2020). Frontiers in Immunology. 11:1-13.
  15. Q. Wang et al. (2014). Human Gene Therapy Methods. 25:261-268.
  16. G. Pandey et al. (2013). Nat Med. 19(10): 1318-1324.
  17. A. Follenzi et al. (2012). Blood. 119(23): 5532-5542.